CN103520197B - 作为受损伤口愈合组合物的抗连接蛋白多核苷酸 - Google Patents

作为受损伤口愈合组合物的抗连接蛋白多核苷酸 Download PDF

Info

Publication number
CN103520197B
CN103520197B CN201310392821.XA CN201310392821A CN103520197B CN 103520197 B CN103520197 B CN 103520197B CN 201310392821 A CN201310392821 A CN 201310392821A CN 103520197 B CN103520197 B CN 103520197B
Authority
CN
China
Prior art keywords
application
composition
wound
oligodeoxynucleotide
polynucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310392821.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103520197A (zh
Inventor
戴维·L·贝克尔
科林·R·格林
布拉德福德·J·杜夫特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Treatment Co Ltd
Original Assignee
Medical Treatment Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Treatment Co Ltd filed Critical Medical Treatment Co Ltd
Publication of CN103520197A publication Critical patent/CN103520197A/zh
Application granted granted Critical
Publication of CN103520197B publication Critical patent/CN103520197B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201310392821.XA 2006-12-11 2007-12-11 作为受损伤口愈合组合物的抗连接蛋白多核苷酸 Expired - Fee Related CN103520197B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87440406P 2006-12-11 2006-12-11
US60/874,404 2006-12-11
CN200780051207.XA CN101835476B (zh) 2006-12-11 2007-12-11 作为受损伤口愈合组合物的抗连接蛋白多核苷酸

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200780051207.XA Division CN101835476B (zh) 2006-12-11 2007-12-11 作为受损伤口愈合组合物的抗连接蛋白多核苷酸

Publications (2)

Publication Number Publication Date
CN103520197A CN103520197A (zh) 2014-01-22
CN103520197B true CN103520197B (zh) 2017-11-21

Family

ID=39386432

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310392821.XA Expired - Fee Related CN103520197B (zh) 2006-12-11 2007-12-11 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
CN200780051207.XA Expired - Fee Related CN101835476B (zh) 2006-12-11 2007-12-11 作为受损伤口愈合组合物的抗连接蛋白多核苷酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200780051207.XA Expired - Fee Related CN101835476B (zh) 2006-12-11 2007-12-11 作为受损伤口愈合组合物的抗连接蛋白多核苷酸

Country Status (15)

Country Link
US (5) US8063023B2 (enExample)
EP (3) EP2543378A1 (enExample)
JP (3) JP5431949B2 (enExample)
KR (1) KR101521306B1 (enExample)
CN (2) CN103520197B (enExample)
AU (1) AU2007333535B2 (enExample)
BR (1) BRPI0721094A2 (enExample)
CA (1) CA2672220A1 (enExample)
DK (1) DK2101791T3 (enExample)
ES (1) ES2527131T3 (enExample)
PL (1) PL2101791T3 (enExample)
PT (1) PT2101791E (enExample)
RU (1) RU2521329C2 (enExample)
SI (1) SI2101791T1 (enExample)
WO (1) WO2008073479A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573131B (zh) 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
PL2101791T3 (pl) 2006-12-11 2015-04-30 Coda Therapeutics Inc Preparaty i metody leczenia ran z nieprawidłowym przebiegiem gojenia
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
CN102920996A (zh) * 2007-12-11 2013-02-13 科达治疗公司 受损伤口愈合的药物组合物
AU2008335717A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
EP2237795A2 (en) * 2007-12-21 2010-10-13 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
CA2710380A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions
WO2012076985A2 (en) * 2010-12-06 2012-06-14 The University Of British Columbia Granzyme b inhibitor compositions, methods and uses for promoting wound healing
GB201117538D0 (en) * 2011-10-11 2011-11-23 Royal Veterinary College The Methods
MX351881B (es) 2012-03-01 2017-11-01 Firststring Res Inc Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).
JP2015513905A (ja) * 2012-03-27 2015-05-18 コーダ セラピューティクス， インコーポレイテッド カドヘリン調節に基づく組成物および処置
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
CA2941140A1 (en) * 2014-03-14 2015-09-17 Coda Therapeutics Treatment of resistant lesions
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
US10450569B2 (en) * 2015-08-13 2019-10-22 Somagenics, Inc. Methods and compositions of short small hairpin RNAS and microRNAS for wound healing
WO2018060144A1 (en) * 2016-09-27 2018-04-05 Smith & Nephew Plc Wound closure devices with dissolvable portions
CN111201247A (zh) 2017-04-28 2020-05-26 奥克兰联合服务有限公司 治疗方法和新颖构建体
CN108588075A (zh) * 2018-05-03 2018-09-28 天德悦（北京）生物科技有限责任公司 人Cx43基因干扰序列、shRNA-Cx43病毒及低表达Cx43蛋白的细胞系
US12138293B2 (en) 2020-10-22 2024-11-12 Xequel Bio, Inc. Peptide formulations and ophthalmic uses thereof
RU2754383C1 (ru) * 2020-12-07 2021-09-01 Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) Способ лечения неинфицированного послеоперационного раневого дефекта стопы при отсутствии признаков критической ишемии конечности у больных с нейропатической и нейроишемической формой синдрома диабетической стопы
US12667586B2 (en) 2023-03-07 2026-06-30 Glaukos Corporation Treatments for ocular surface disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044409A1 (en) * 1999-01-27 2000-08-03 University College London Formulations comprising antisense nucleotides to connexins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0539594Y2 (enExample) 1988-08-05 1993-10-07
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
GB9425930D0 (en) 1994-12-22 1995-02-22 Procter & Gamble Silicone compositions
EP0950060A4 (en) 1996-12-02 2000-07-05 Dyad Pharmaceutical Corp COUNTERSTRAIN INHIBITION OF HUMAN ADHESION MOLECULES
RU2147240C1 (ru) * 1998-02-16 2000-04-10 Рязанский областной клинический кожно-венерологический диспансер Препарат для лечения длительно незаживающих инфицированных язв и ран
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
JP2005509621A (ja) 2001-10-17 2005-04-14 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン ギャップ結合ならびにｅｄｈｆ
CN1939529A (zh) 2002-01-29 2007-04-04 Wyeth公司 用于调节连接蛋白半通道的组合物和方法
CN1922320B (zh) * 2003-12-03 2013-04-24 科达治疗（新西兰）有限公司 靶向连接蛋白的反义化合物及其使用方法
DE102004027422A1 (de) 2004-06-04 2005-12-29 Boehringer Ingelheim Microparts Gmbh Vorrichtung zur Aufnahme von Blut und Abtrennung von Blutbestandteilen
EP1827480B1 (en) 2004-12-21 2016-11-09 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
CN101573131B (zh) * 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
PL2101791T3 (pl) 2006-12-11 2015-04-30 Coda Therapeutics Inc Preparaty i metody leczenia ran z nieprawidłowym przebiegiem gojenia
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
AU2008335717A1 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
CN102920996A (zh) 2007-12-11 2013-02-13 科达治疗公司 受损伤口愈合的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044409A1 (en) * 1999-01-27 2000-08-03 University College London Formulations comprising antisense nucleotides to connexins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Targeting Connexin43 Expression Accelerates the Rate of Wound Repair;Cindy Qiu et al.;《Current Biology》;20030930;第13卷;第1697-1703页 *

Also Published As

Publication number Publication date
CN103520197A (zh) 2014-01-22
JP5911454B2 (ja) 2016-04-27
JP2010512404A (ja) 2010-04-22
RU2009126594A (ru) 2011-01-20
US20120289579A1 (en) 2012-11-15
US8063023B2 (en) 2011-11-22
AU2007333535B2 (en) 2014-04-17
JP2015063565A (ja) 2015-04-09
JP2013173796A (ja) 2013-09-05
RU2521329C2 (ru) 2014-06-27
US8685940B2 (en) 2014-04-01
US20080242631A1 (en) 2008-10-02
CN101835476A (zh) 2010-09-15
EP2543377A1 (en) 2013-01-09
WO2008073479A2 (en) 2008-06-19
CN101835476B (zh) 2016-08-17
EP2101791A2 (en) 2009-09-23
US20130143952A1 (en) 2013-06-06
HK1136213A1 (en) 2010-06-25
WO2008073479A3 (en) 2008-08-07
BRPI0721094A2 (pt) 2014-02-11
US20170240905A1 (en) 2017-08-24
PT2101791E (pt) 2014-12-18
CA2672220A1 (en) 2008-06-19
PL2101791T3 (pl) 2015-04-30
EP2101791B1 (en) 2014-09-10
US9637745B2 (en) 2017-05-02
EP2543378A1 (en) 2013-01-09
JP5431949B2 (ja) 2014-03-05
US9029339B2 (en) 2015-05-12
DK2101791T3 (en) 2015-01-05
KR20090118910A (ko) 2009-11-18
KR101521306B1 (ko) 2015-05-18
SI2101791T1 (sl) 2015-02-27
US20150315598A1 (en) 2015-11-05
AU2007333535A1 (en) 2008-06-19
ES2527131T3 (es) 2015-01-20

Similar Documents

Publication Publication Date Title
JP5911454B2 (ja) 減損した創傷治癒の組成物としての抗コネキシンポリヌクレオチド
CN102920996A (zh) 受损伤口愈合的药物组合物
US20110130710A1 (en) Treatment of abnormal or excessive scars
US9156896B2 (en) Wound healing compositions and treatments
JP2017148075A (ja) 創傷治癒組成物および治療
CN107080845A (zh) 受损伤口愈合的组合物和治疗
JP2015057430A (ja) 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
AU2008343841A1 (en) Use of inhibitors of connexin43 for treatment of fibrotic conditions
JP2015013880A (ja) 外科的癒着の治療のための抗コネキシンポリヌクレオチドの使用
AU2015201309A1 (en) Treatment of fibrotic conditions
HK1136213B (en) Anticonnexin polynucleotides as impaired wound healing compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: American California

Applicant after: Medical Treatment Co Ltd

Address before: American California

Applicant before: Coda Therapeutics Inc.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20171121

Termination date: 20201211

CF01 Termination of patent right due to non-payment of annual fee